Search all trials

Find therapies in clinical trials near you – page 5

Search by disease and location to discover available clinical trials matching your criteria. Updated every day from authoritative EU registries.

recruiting: 3 961
countries: 28
conditions: 2 103

3 961 trials recruiting28 European countries2 103 conditions coveredUpdated today

Quick filters

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Registered drugNo placebo

Study Comparing Two Treatment Sequences of CDK4/6 Inhibitors (Abemaciclib, Palbociclib, or Ribociclib) in Hormone Receptor Positive Advanced Breast Cancer

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Abemaciclib

Contact Research Centre

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Registered drug

Study Comparing Camizestrant and Palbociclib with Anastrozole and Palbociclib for Patients with ER-Positive, HER2-Negative Advanced Breast Cancer Without Prior Treatment

Registered drug

Austria

Participants:18–64 years · 65+ years
Substances:Anastrozole

Contact Research Centre

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Registered drugNo placebo

Study on Metformin to Prevent High Blood Sugar in Advanced Breast Cancer Patients with Alpelisib and Endocrine Therapy

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Alpelisib

Contact Research Centre

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Registered drugNo placebo

Study on Reducing Hormone Therapy Duration with Exemestane, Letrozole, and Anastrozole in Post-Menopausal Women with Low-Risk Hormone-Sensitive Breast Cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Anastrozole

Contact Research Centre

Hormone receptor positive HER2 negative breast cancer+3

Not recruiting

Registered drugNo placebo

Study on Giredestrant and Everolimus for Patients with Estrogen Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Everolimus

Contact Research Centre

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Registered drugNo placebo

Study of palbociclib with hormone therapy guided by ESR1 mutation monitoring in patients with ER-positive, HER2-negative metastatic breast cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Anastrozole

Contact Research Centre

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Registered drugNo placebo

Study Comparing Datopotamab Deruxtecan to Chemotherapy in Patients with Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Capecitabine

Contact Research Centre

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Registered drugNo placebo

Study on Sacituzumab Govitecan for Patients with Advanced or Metastatic HR+/HER2- Breast Cancer Resistant to Hormone and CDK4/6 Inhibitors

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Sacituzumab Govitecan

Contact Research Centre

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Registered drug

Study of Pembrolizumab with Chemotherapy for High-Risk Early-Stage ER+/HER2- Breast Cancer Patients

Registered drug

Belgium

Participants:18–64 years · 65+ years
Substances:Doxorubicin

Contact Research Centre

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Registered drugNo placebo

Study on Pembrolizumab and Paclitaxel for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer in Patients Resistant to CDK 4/6 Inhibitors

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Pembrolizumab

Contact Research Centre

Hormone receptor positive HER2 negative breast cancer

Not recruiting

InvestigationalNo placebo

Study of Patritumab Deruxtecan with or without Endocrine Therapy for High-Risk HR+/HER2- Early Breast Cancer in Untreated Patients

InvestigationalNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Patritumab Deruxtecan

Contact Research Centre

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Registered drugNo placebo

Study of Capivasertib with CDK4/6 Inhibitors and Fulvestrant for Patients with Advanced HR+/HER2- Breast Cancer

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Abemaciclib

Contact Research Centre

Find therapies in clinical trials near you – page 5

62 trials match your criteria

Hormone receptor positive HER2 negative breast cancer

Study Comparing Two Treatment Sequences of CDK4/6 Inhibitors (Abemaciclib, Palbociclib, or Ribociclib) in Hormone Receptor Positive Advanced Breast Cancer

Hormone receptor positive HER2 negative breast cancer

Study Comparing Camizestrant and Palbociclib with Anastrozole and Palbociclib for Patients with ER-Positive, HER2-Negative Advanced Breast Cancer Without Prior Treatment

Hormone receptor positive HER2 negative breast cancer

Study on Metformin to Prevent High Blood Sugar in Advanced Breast Cancer Patients with Alpelisib and Endocrine Therapy

Hormone receptor positive HER2 negative breast cancer

Study on Reducing Hormone Therapy Duration with Exemestane, Letrozole, and Anastrozole in Post-Menopausal Women with Low-Risk Hormone-Sensitive Breast Cancer

Hormone receptor positive HER2 negative breast cancer+3

Study on Giredestrant and Everolimus for Patients with Estrogen Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer

Hormone receptor positive HER2 negative breast cancer

Study of palbociclib with hormone therapy guided by ESR1 mutation monitoring in patients with ER-positive, HER2-negative metastatic breast cancer

Hormone receptor positive HER2 negative breast cancer

Study Comparing Datopotamab Deruxtecan to Chemotherapy in Patients with Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

Hormone receptor positive HER2 negative breast cancer

Study on Sacituzumab Govitecan for Patients with Advanced or Metastatic HR+/HER2- Breast Cancer Resistant to Hormone and CDK4/6 Inhibitors

Hormone receptor positive HER2 negative breast cancer

Study of Pembrolizumab with Chemotherapy for High-Risk Early-Stage ER+/HER2- Breast Cancer Patients

Hormone receptor positive HER2 negative breast cancer

Study on Pembrolizumab and Paclitaxel for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer in Patients Resistant to CDK 4/6 Inhibitors

Hormone receptor positive HER2 negative breast cancer

Study of Patritumab Deruxtecan with or without Endocrine Therapy for High-Risk HR+/HER2- Early Breast Cancer in Untreated Patients

Hormone receptor positive HER2 negative breast cancer

Study of Capivasertib with CDK4/6 Inhibitors and Fulvestrant for Patients with Advanced HR+/HER2- Breast Cancer

Explore other searches

Vaccine trials

Paediatric trials · ages 0–17

Healthy volunteers

Helpful resources

How applying through us works

What happens after you apply

Guides for patients and volunteers

Search filters

Prefer not to search? Our Concierge searches the trials for you.